We have an opening for a talented Postdoctoral Fellow to join the laboratory of Dr. Anwesha Dey in the Discovery Oncology Department at Genentech. The focus of the lab is to use biochemical and cellular approaches to study signaling pathways in cancer. The potential project will be focused on mechanistic understanding of the hippo signaling pathway in cancer using biochemical approaches in relevant cellular models. The lab has access to state of the art mass spectrometry facilities, automation for high-throughput screening as well as access to in vivo mouse models.
Who You Are:
The successful candidate must
- Be able to demonstrate scientific rigor and a willingness to collaborate with a multidisciplinary team of scientists
- Have excellent communication and writing skills as well as a track record of working in highly collaborative environments
- Have at least one first author paper published or accepted in a peer-reviewed journal
The qualified individual will have
- A PhD in Biochemistry, Molecular or Cell Biology or related field
- Experience in cellular experiments (tissue culture, IP western, signaling experiments, siRNA/CRISPR) using mammalian tumor cell lines
- Experience with mouse models is a plus
- Candidates who are computationally competent to analyze omics data will be preferred
More information about the Dey Lab:
More information about the Genentech Postdoctoral Program:
Representative Lab Publications
Pham T, Hagenbeek T, Lee H, Li J, Rose CM, Lin E, Yu M, Martin S, Piskol R, Lacap J, Sampath D, Pham V, Modrusan M, Lill J, Klijn C, Malek S, Chang M, Dey A. Cancer Discovery, 2020 (Accepted manuscript) Machine learning and chemico-genomics approach defines and predicts cross-talk of Hippo and MAPK pathways.
Dey A*, Varelas X and Guan KL. Nature Reviews Drug Discovery. 2020 Targeting the Hippo pathway in cancer, fibrosis, wound healing and regeneration. * Co-corresponding author.
Lee HJ, Pham T, Chang MT, Barnes D, Cai AG, Noubade R, Totpal K, Chen X, Tran C, Hagenbeek T, Wu X, Eastham-Anderson J, Tao J, Lee W, Bastian BC, Carbone M, Webster JD, Dey A. Cancer Res. 2020 Jan 27. The tumor suppressor BAP1 regulates the hippo pathway in pancreatic ductal adenocarcinoma.
Calses P, Lill J, Crawford J, Dey A. Trends in Cancer. 2019 May;5(5):297-307. Hippo pathway in cancer: Aberrant Regulation and Therapeutic Opportunities.
Hagenbeek T, Kljavin N, Webster J, Klijn C, Cai A, Totpal K, Ravishankar B, Yang N, Walsh K, Hatzivassiliou G, Modrusan Z, de la Cruz C, Gould S, Wu X, Lee W, Jackson E, Dey A. Science Signaling. 2018 Sep 11;11(547). The Hippo pathway effector TAZ induces TEAD dependent liver inflammation and transformation.
Arenzana TL, Lianoglou S, Seki A, Eidenschenk C, Cheung T, Seshasayee D, Hagenbeek T, Sambandam A, Noubade R, Peng I, Lesch J, DeVoss J, Wu X, Lee WP, Caplazi P, Webster J, Liu J, Pham VC, Arnott D, Lill JR, Modrusan Z, Dey A*, Rutz S*. Science Immunology, 2018 Apr 20;3(22). Tumor Suppressor BAP1 is essential for maintenance and function of the T lymphocyte lineage. * Co- corresponding author.